Folate Receptor Alpha (FRα) is overexpressed in a range of solid tumors with limited expression in normal tissues, hence an attractive target for an antibody-drug conjugate (ADC). 

Rina-S is comprised of a human monoclonal antibody that selectively binds human FRα, a novel cleavable hydrophilic linker, and a topoisomerase 1 inhibitor payload, exatecan. 

Rina-S demonstrates anti-tumor activity in patients with endometrial and ovarian cancer (SITC 2023) at well tolerated dose levels. 

A first in human phase 1/2 study in patients with advanced solid tumors is currently recruiting (NCT 05579366). 

Expanded Access Program